DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Gepotidacin
Gepotidacin
Overcoming Fluoroquinolone Resistance: Mechanistic Basis of Non- Quinolone Antibacterials Targeting Type Ii Topoisomerases
Gonorrhea, Chlamydia, and Syphilis
Anew Drug Design Strategy in the Liht of Molecular Hybridization Concept
The Study Listed May Include Approved and Non-Approved Uses, Formulations Or Treatment Regimens
Analysis of the Clinical Antibacterial and Antituberculosis Pipeline
Performance Standards for Antimicrobial Susceptibility Testing
Files of Purified Oligog-Drug Conjugates
Influence of Ph on the Activity of Finafloxacin Against Extracellular
Table of Suggested Abbreviations Using the EUCAST System* Entries in Orange Required Application of the Rules
2020 Antibacterial Agents in Clinical and Preclinical
Development of New Novel Bacterial Topoisomerase Inhibitors As Promising Antibiotics with a 5-Amino-1,3-Dioxane Linker Moiety DI
Antibiotics Currently in Clinical Development
Discovery of Novel Antibiotics Via Streptomyces Sporulation by Scott
Rapid Evolution of Reduced Susceptibility Against a Balanced Dual-Targeting Antibiotic Through Stepping-Stone Mutations
Contents • February 2017 • Volume 61, No. 2
2019 Antibacterial Agents in Clinical Development
Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: a Phase 2, Randomized, Dose- XX Ranging, Single-Oral Dose Evaluation Stephanie N
Bacterial Targets of Antibiotics in Methicillin-Resistant Staphylococcus Aureus
Top View
Topoisomerase
Study Protocol
Antimicrobial Resistance Benchmark 2018
Antibiotics in the Clinical Pipeline in October 2019
New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives
Antibiotic Usage Promotes the Evolution of Resistance Against Gepotidacin, a Novel Multi-Targeting Drug
Literature Search Strategy for Treatment of Stable
19-GSK-01 Gepo.Indd
Directed Evolution of Multiple Genomic Loci Allows the Prediction of Antibiotic Resistance
Antibiotics Currently in Clinical Development Note: This Data Visualization Was Updated in December 2016 with New Data
S. Aureus, S. Pneumoniae and E
Recent Progress in the Development of Small-Molecule Ftsz Inhibitors As Chemical Tools for the Development of Novel Antibiotics
Anti-Infection
Sexually Transmitted Infections Caused by Mycoplasma
Microorganisms
Antibiotics in Late Clinical Development
Antibiotic Disc Antibiotic Discs for Susceptibility Tests
M100 Performance Standards for Antimicrobial Susceptibility Testing
P1849 in Vitro Activities of Gepotidacin, a Novel Triazaacenaphthylene Topoisomerase IV and DNA Gyrase Inhibitor, Against Gram-N
Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance
Medchemcomm Accepted Manuscript
Gepotidacin (GSK2140944) in Vitro Activity Against Neisseria Gonorrhoeae (MIC/MBC, Kill Robert K
Antibacterial Drug R&D
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Gonorrhea - Uncomplicated Anogenital Infection (1 of 10)